Previous close | 748.80 |
Open | 750.10 |
Bid | 738.90 x 0 |
Ask | 742.90 x 0 |
Day's range | 737.20 - 755.00 |
52-week range | 475.45 - 834.50 |
Volume | |
Avg. volume | 2,075,988 |
Market cap | 1.684T |
Beta (5Y monthly) | 0.32 |
PE ratio (TTM) | 34.55 |
EPS (TTM) | 21.50 |
Earnings date | N/A |
Forward dividend & yield | 10.40 (1.39%) |
Ex-dividend date | 25 Mar 2022 |
1y target est | 784.25 |
Bagsværd, Denmark, 16 May 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiate
Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.
A question on the minds of many investors right now is how economic uncertainty will continue to affect large cap companies, such as Novo Nordisk A/S (CPH:NOVO...